FOR IMMEDIATE RELEASE

Nebraska Cultures Announces Sponsorship of
Clinical Study on Efficacy of DDS-1 Strain of
L. acidophilus

Landmark study seeks to identify the survivability
of “good” bacteria in the human digestive system

WALNUT CREEK, Calif. (March 02, 2010) – Nebraska Cultures Inc.
(www.nebraskacultures.com), the creator and exclusive supplier of Dr. Shahani’s® DDS-1
strain of L. acidophilus, today announced that the company is sponsoring a much-awaited
and definitive study on the efficacy of probiotics in human . The study, entitled Survival
and persistence of Lactobacillus acidophilus DDS-1 and other lactobacilli in human
subjects, specifically seeks to determine whether healthy bacteria can survive an extended
time in the human gastrointestinal (GI) tract. Because of the low pH, the presence of bile
salts and the competitive environment of the human intestinal tract, questions have arisen
regarding the survivability (and therefore efficacy) of probiotics as a category. For
accuracy and relevance to Dr. Shahani’s original strain of probiotic, the study will employ
human trial subjects who ingest controlled amounts of specified bacteria strains, and who
are then tested after an extended period of time to see what, if any, of the bacteria can still
be detected.

“With US consumers spending tens of millions a year on vitamins, supplements and other
holistic medicines, we feel it is important for our company to regularly revisit the topic of efficacy for our loyal customers,” explained Michael Shahani, director of operations for
Nebraska Cultures. “A strong research base and ongoing innovation has always been
what has separated us from our competition, so it was natural for us to sponsor this human
trial to better understand the role that good bacteria play in our wellbeing. Results from
this study will allow us to further refine our healthful products to better restore the natural
balance of the human body.”

The study will be conducted by the University of Nebraska, Department of Food Science
and Technology, under the guidance of noted probiotic scientist Robert Hutkins, as well as
Jens Walter and Steven Frese. The study will assess the ability of a commercially
available, widely studied probiotic strain, Lactobacillus acidophilus DDS-1, and two other
lactobacilli to survive through the stomach and persist in the human gastrointestinal tract.

“We are excited about releasing the results of this study in the near future, which will
further substantiate the role that Dr. Shahani’s strain of DDS-1 L. acidophilus has had on
the probiotics industry,” Michael added.

The study will be released by Nebraska Cultures later this year.


About Nebraska Cultures
Since 1981, Nebraska Cultures has supplied the natural products industry with the finest probiotic cultures – the Dr. Shahani's® brand – specializing in the DDS-1 strain of L. acidophilus. Nebraska Cultures remains at the forefront of the probiotic industry by performing new research, increasing consumer awareness, growing its business overseas and expanding into functional foods.

As one of the most influential probiotics scientists to date, Dr. Khem Shahani began his landmark research on Lactobacillus acidophilus at the University of Nebraska in the late 1950s. There he discovered a particular strain of L. acidophilus that showed superior growth, stability (clinical studies) and nutritional viability. Dr. Shahani would later name the strain DDS-1 for the Department of Dairy Science Number One strain and spend the rest of his career unlocking its potentials for improving overall health.